Slate Medicines
PrivateLast Round
Series A
Feb 24, 2026
Total Funding Raised
$130M
Company Overview
Slate Medicines is a biotechnology company developing next-generation therapeutics targeting PACAP for the treatment and prevention of migraine and other headache disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Slate Medicines Comparables
Compare Slate Medicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Vedana Therapeutics | 90% | |
| DartsBio Pharmaceutical (Guangdong) Co., Ltd. | 85% | |
| InMed Pharmaceuticals | 84% | |
Slate Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Feb 24, 2026 |
Key People
Founding team and executive leadership
Slate Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series A |
| RA Capital Management | Series A |
| Forbion | Series A |
| Foresite Capital | Series A |
Slate Medicines Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Slate Medicines's valuation, stock price, and market status.